Investigational New Drugs : Impact Factor & More
eISSN: 1573-0646pISSN: 0167-6997
Share this on:
Key Metrics
CiteScore 
6.2
Eigenfactor
0.005 - 0.01
H-Index
94
Impact Factor
< 5
SJR
Q1Oncology
SNIP
0.85
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Investigational New Drugs
Investigational New Drugs Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Bi-monthly |
| General Details | |
| Language | English |
| Frequency | Bi-monthly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Investigational New Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Investigational New Drugs
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer.
- 18 May 2026
- Investigational new drugs
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.
- 16 May 2026
- Investigational new drugs
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.
- 4 May 2026
- Investigational new drugs
Prostate cancer cells' growth is decreased by novel MYC inhibitors.
- 28 Apr 2026
- Investigational new drugs
Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes.
- 22 Apr 2026
- Investigational new drugs
A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
- 14 Apr 2026
- Investigational new drugs
Preclinical and clinical evaluation of futibatinib in combination with binimetinib in patients with advanced cancer.
- 18 May 2026
- Investigational new drugs
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer.
- 16 May 2026
- Investigational new drugs
Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumors.
- 4 May 2026
- Investigational new drugs
Prostate cancer cells' growth is decreased by novel MYC inhibitors.
- 28 Apr 2026
- Investigational new drugs
Spatial blueprint of colorectal cancer identifies Hypoxic CAF program that orchestrates Go-or-Grow decisions and predicts outcomes.
- 22 Apr 2026
- Investigational new drugs
A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors.
- 14 Apr 2026
- Investigational new drugs
FAQs on Investigational New Drugs
How long has Investigational New Drugs been actively publishing? 
What is the publishing frequency of Investigational New Drugs?
How many articles did Investigational New Drugs publish last year?
What is the eISSN & pISSN for Investigational New Drugs?
What is Citescore for Investigational New Drugs?
What is the H Index for Investigational New Drugs ?
What is SNIP score for Investigational New Drugs?
What is the SJR for Investigational New Drugs?
Who is the publisher of Investigational New Drugs?
